NCPIC - National Cannabis Prevention and Information Centre

Publications Bulletin - October 2012

Relevant publications examining issues to do with cannabis that have been published in the last month include the following:

  • Bosker, W.M., Kuypers, K.P., Theunissen, E.L., Surinx, A., Blankespoor, R.J., Skopp, G., Jeffery, W.K., Walls, H.C., van Leeuwen C.J., & Ramaekers, J.G. (2012). Medicinal Δ(9) -tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. Addiction 107, 1837-1844.
  • Bruci, Z., Papoutsis, I., Athanaselis, S., Nikolaou, P., Pazari, E., Spiliopoulou, C., & Vyshka, G. (2012). First systematic evaluation of the potency of cannabis sativa plants grown in Albania. Forensic Science International 222, 40-46.
  • Bujarski, S.J., Norberg, M.M. & Copeland, J. (2012). The association between distress tolerance and cannabis use-related problems: The mediating and moderating roles of coping motives and gender. Addictive Behaviors 37, 1181-1184.
  • Chabrol, H., Chauchard, E., Goutaudier, N., & van Leeuwen, N. (2012). Exploratory study of the psychopathological profiles of adolescent cannabis users. Addictive Behaviors 37, 1109-1113.
  • Faridi, K., Joober, R. & Malla, A. (2012). Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis. Schizophrenia Research 141, 78-82.
  • Kleinloog, D., Liem-Moolenaar, M., Jacobs, G., Klaassen, E., de Kam, M., Hijman, R., & van Gerven, J. (2012). Does Olanzapine inhibit the psychomimetic effects of Delta-9-tetrahydrocannabinol? Journal of Psychopharmacology 26, 1307-1316.
  • Kopak, A.M., Proctor, S.L. & Hoffmann, N.G. (2012). An assessment of the compatibility of DSM-IV and proposed DSM-5 criteria in the diagnosis of cannabis use disorders. Substance Use and Misuse 47, 1328-1338.
  • Lecompte, Y., Perrin, M., Salle, S., & Roussel, O. (2012). Impact of lowering confirmatory test cutoff value in pre-enlistment urine cannabinoids screening: About five years' experience in the French gendarmerie. Journal of Analytical Toxicology 36, 569-574.
  • Lynskey, M.T., Agrawal, A., Henders, A., Nelson, E.C., Madden, P.A., & Martin, N.G. (2012). An Australian twin study of cannabis and other illicit drug use and misuse, and other psychopathology. Twin Research and Human Genetics 15, 631-641.
  • O'Tuathaigh, C.M., Clarke, G., Walsh, J., Desbonnet, L., Petit, E., O'Leary, C., Tighe, O., Clarke, N., Karayiorgou, M., Gogos, J.A., Dinan, T.G., Cryan, J.F., & Waddington, J.L. (2012). Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. International Journal of Neuropsychopharmacology 15, 1331-1342.
  • Piontek, D., Kraus, L., Pabst, A., & Legleye, S. (2012). An age-period-cohort analysis of cannabis use prevalence and frequency in Germany, 1990-2009. Journal of Epidemiology and Community Health 66, 908-913.
  • Ranganathan, M., Carbuto, M., Braley, G., Elander, J., Perry, E., Pittman, B., Radhakrishnan, R., Sewell, R.A., & D'Souza, D.C. (2012). Naltrexone does not attenuate the effects of intravenous Delta-9-tetrahydrocannabinol in healthy humans. International Journal of Neuropsychopharmacology 15, 1251-1264.
  • Taffe, M.A. (2012). Delta-9-tetrahydrocannabinol impairs visuo-spatial associative learning and spatial working memory in rhesus macaques. Journal of Psychopharmacology 26, 1299-1306.